A. Sacré, “Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor”, AO, vol. 55, no. 3, pp. 329–340, Mar. 2016.